



TF

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Wilfried Braje et al. ) Examiner: Unknown  
Serial No.: 10/583,590 ) Group Art Unit: Unknown  
Filed: 06/19/2006 ) Confirmation No.  
For: Tetrahydrobenzazepines and ) Atty. Dkt.: ABB10010P00962US  
their use in the modulation )  
of the dopamine D<sub>3</sub> receptor )

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Copies of the literature references and foreign patents are enclosed.

WO 96/02519, WO 96/02520, WO 96/02249, WO 96/02246, WO 99/02503 and DE 10 131 543 are not available in English, however, an English language abstract is contained on the front page of the reference and a concise explanation of the relevance of the references is discussed in the previously-submitted International Search Report.

Entry in to the record is respectfully requested.

Respectfully submitted


By Martin L. Katz  
Martin L. Katz, Reg. No. 25,011

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER  
Citigroup Center, Suite 3800  
500 West Madison Street  
Chicago, Illinois 60661  
312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this paper, Form SB/08A and cited references are being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on August 24, 2006

Stephanie Frain  
Stephanie Frain



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/583,590
				Filing Date	06/19/2006
				First Named Inventor	Wilfried Braje et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	2	Attorney Docket No.	ABB10010P00962US

**U.S. PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 96/02519	02/01/1996	BASF Aktiengesellschaft		
		WO 96/02520	02/01/1996	BASF Aktiengesellschaft		
		WO 96/02249	02/01/1996	BASF Aktiengesellschaft		
		WO 96/02246	02/01/1996	BASF Aktiengesellschaft		
		WO 99/02503	01/21/1999	BASF Aktiengesellschaft		
		WO 00/21951	04/20/2000	SmithKline Beechman PLC		
		WO 02/40471	05/23/2002	SmithKline Beechman PLC		
		WO 03/68732	08/21/2003	Glaxo Group Limited		
		WO 03/68751	08/21/2003	Glaxo Group Limited		
		WO 03/68752	08/21/2003	Glaxo Group Limited		
		WO 02/40471	05/23/2002	SmithKline Beechman PLC		
		WO 04/31181	04/15/2004	Glaxo Group Limited		
		DE 10 131 543	01/16/2003	Abbott Laboratories		
Examiner Signature					Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed

application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/583,590
				Filing Date	06/19/2006
				First Named Inventor	Wilfried Braje et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket No.	ABB10010P00962US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SCHWARTZ J C ET AL <i>The Dopamine D3 Receptor as a Target for Antipsychotics</i> Novel Antipsychotic Drugs, H.Y. Meltzer, ed., Raven Press, New York (1992) pp. 135-144	
		DOOLEY M ET AL <i>Pramipexole A Review of its Use in the Management of Early and Advanced Parkinson's Disease</i> Drugs and Aging Vol. 12 (1998) pp. 495-514	
		JOYCE J N ET AL <i>The Dopamine D3 Receptor as a therapeutic Target for Antipsychotic and Antiparkinsonian Drugs</i> Pharmacology and Therapeutics Vol. 90 (2001) pp. 231-259	
		SOKOLOFF P ET AL <i>Localization and Function of the D3 Dopamine Receptor</i> <i>Arzneim. Forsch./Drug Res.</i> Vol. 42(1) (1992) pp. 224-230	
		SOKOLOFF P ET AL <i>Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics</i> <i>Nature</i> Vol. 347 (1990) pp. 146-151	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.